Download PDF
Gastroenterologie up2date 2014; 10(01): 11-22
DOI: 10.1055/s-0033-1359236
Ösophagus/Magen/Duodenum
© Georg Thieme Verlag KG Stuttgart · New York

Helicobacter pylori

Christian Schulz
,
Peter Malfertheiner
Further Information

Publication History

Publication Date:
27 March 2014 (online)

Also available at
    Permissions and Reprints All articles of this category
Kernaussagen

Klinik

  • Die H.-pylori-Infektion führt immer zu einer chronischen Gastritis, in ca. 20 % zu präkanzerösen Läsionen.

  • Die H.-pylori-Infektion stellt den stärksten Risikofaktor zur Entstehung eines Magenkarzinoms dar.

Therapie

  • Die H.-pylori-Eradikation führt zur Heilung der peptischen Ulkuskrankheit und reduziert Komplikationen einer Langzeit-ASS/NSAR-Therapie.

  • Kenntnisse der lokalen Resistenzlage helfen bei der Steuerung einer optimalen Eradikationstherapie.

  • Nicht invasive Eradikationserfolgskontrollen (13C-Atemtest oder monoklonaler Stuhlantigentest) sind obligat.

  • Eine bismutbasierte Quadrupel-Therapie ist bei Therapieversagen oder hoher lokaler Clarithromycinresistenz verfügbar.

 

  • Literatur

  • 1 Warren JR, Marshall B. Unidentified curved bacilli on gastric epithelium in active chronic gastritis. Lancet 1983; 1: 1273-1275
    PubMedSearch in Google Scholar
  • 2 Campylobacter pylori becomes Helicobacter pylori. Lancet 1989; 2: 1019-1020
    PubMedSearch in Google Scholar
  • 3 Basso D, Zambon C, Letley DP et al. Clinical relevance of Helicobacter pylori cagA and vacA gene polymorphisms. Gastroenterology 2008; 135: 91-99
    CrossrefPubMedSearch in Google Scholar
  • 4 Kusters JG, van Vliet AH, Kuipers EJ. Pathogenesis of Helicobacter pylori infection. Clin Microbiol Rev 2006; 19: 449-490
    CrossrefPubMedSearch in Google Scholar
  • 5 Peek RM, Crabtree JE. Helicobacter infection and gastric neoplasia. J Pathol 2006; 208: 233-248
    CrossrefPubMedSearch in Google Scholar
  • 6 Fischbach W, Malfertheiner P, Hoffmann JC et al. S3-Leitlinie „Helicobacter pylori und gastroduodenale Ulkuskrankheit“ der Deutschen Gesellschaft für Verdauungs- und Stoffwechselkrankheiten (DGVS). Z Gastroenterol 2009; 47: 68-102
    Thieme ConnectPubMedSearch in Google Scholar
  • 7 Malfertheiner P, Megraud F, O’Morain CA et al. Management of Helicobacter pylori infection – the Maastricht IV/ Florence Consensus Report. Gut 2012; 61: 646-664
    CrossrefPubMedSearch in Google Scholar
  • 8 Goh K, Chan W, Shiota S et al. Epidemiology of Helicobacter pylori infection and public health implications. Helicobacter 2011; 16 (Suppl. 01) 1-9
    PubMedSearch in Google Scholar
  • 9 Wex T, Venerito M, Kreutzer J et al. Serological prevalence of Helicobacter pylori infection in Saxony-Anhalt, Germany, in 2010. Clin Vaccine Immunol 2011; 18: 2109-2112
    CrossrefPubMedSearch in Google Scholar
  • 10 Ikenberry SO, Harrison ME, Lichtenstein D et al. The role of endoscopy in dyspepsia. Gastrointest Endosc 2007; 66: 1071-1075
    CrossrefPubMedSearch in Google Scholar
  • 11 Gwee K, Teng L, Wong RM et al. The response of Asian patients with functional dyspepsia to eradication of Helicobacter pylori infection. Eur J Gastroenterol Hepatol 2009; 21: 417-424
    CrossrefPubMedSearch in Google Scholar
  • 12 Chan FK, To KF, Wu JC et al. Eradication of Helicobacter pylori and risk of peptic ulcers in patients starting long-term treatment with non-steroidal anti-inflammatory drugs: a randomised trial. Lancet 2002; 359: 9-13
    CrossrefPubMedSearch in Google Scholar
  • 13 Vergara M, Catalán M, Gisbert JP et al. Meta-analysis: role of Helicobacter pylori eradication in the prevention of peptic ulcer in NSAID users. Aliment Pharmacol Ther 2005; 21: 1411-1418
    CrossrefPubMedSearch in Google Scholar
  • 14 Chan FK, Chung SC, Suen BY et al. Preventing recurrent upper gastrointestinal bleeding in patients with Helicobacter pylori infection who are taking low-dose aspirin or naproxen. N Engl J Med 2001; 344: 967-973
    CrossrefPubMedSearch in Google Scholar
  • 15 Chan FK, Ching JY, Suen BY et al. Effects of Helicobacter pylori infection on long-term risk of peptic ulcer bleeding in low-dose aspirin users. Gastroenterology 2013; 144: 528-535
    CrossrefPubMedSearch in Google Scholar
  • 16 Stasi R, Sarpatwari A, Segal JB et al. Effects of eradication of Helicobacter pylori infection in patients with immune thrombocytopenic purpura: a systematic review. Blood 2009; 113: 1231-1240
    CrossrefPubMedSearch in Google Scholar
  • 17 Muhsen K, Cohen D. Helicobacter pylori infection and iron stores: a systematic review and meta-analysis. Helicobacter 2008; 13: 323-340
    CrossrefPubMedSearch in Google Scholar
  • 18 Chen Y, Blaser MJ. Inverse associations of Helicobacter pylori with asthma and allergy. Arch Intern Med 2007; 167: 821-827
    CrossrefPubMedSearch in Google Scholar
  • 19 Fullerton D, Britton JR, Lewis SA et al. Helicobacter pylori and lung function, asthma, atopy and allergic disease – a population-based cross-sectional study in adults. Int J Epidemiol 2009; 38: 419-426
    CrossrefPubMedSearch in Google Scholar
  • 20 Ioannou GN, Weiss NS, Kearney DJ. Is Helicobacter pylori seropositivity related to body mass index in the United States?. Aliment Pharmacol Ther 2005; 21: 765-772
    CrossrefPubMedSearch in Google Scholar
  • 21 Chen Y, Blaser MJ. Association between gastric Helicobacter pylori colonization and glycated hemoglobin levels. J Infect Dis 2012; 205: 1195-1202
    CrossrefPubMedSearch in Google Scholar
  • 22 Jeffery PL, McGuckin MA, Linden SK. Endocrine impact of Helicobacter pylori: focus on ghrelin and ghrelin o-acyltransferase. World J. Gastroenterol 2011; 17 : 1249-1260
    CrossrefPubMedSearch in Google Scholar
  • 23 Saad AM, Choudhary A, Bechtold ML. Effect of Helicobacter pylori treatment on gastroesophageal reflux disease (GERD): meta-analysis of randomized controlled trials. Scand J Gastroenterol 2012; 47: 129-135
    CrossrefPubMedSearch in Google Scholar
  • 24 Seifert E, Schulte F, Stolte M. Long-term results of treatment of malignant non-Hodgkin’s lymphoma of the stomach. Z Gastroenterol 1992; 30: 505-508
    PubMedSearch in Google Scholar
  • 25 Stolte M. Helicobacter pylori gastritis and gastric MALT-lymphoma. Lancet 1992; 339: 745-746
    PubMedSearch in Google Scholar
  • 26 Wotherspoon AC, Ortiz-Hidalgo C, Falzon MR et al. Helicobacter pylori-associated gastritis and primary B-cell gastric lymphoma. Lancet 1991; 338: 1175-1176
    CrossrefPubMedSearch in Google Scholar
  • 27 Ruskoné-Fourmestraux A, Fischbach W, Aleman BM et al. EGILS consensus report. Gastric extranodal marginal zone B-cell lymphoma of MALT. Gut 2011; 60: 747-758
    CrossrefPubMedSearch in Google Scholar
  • 28 Nakamura S, Sugiyama T, Matsumoto T et al. Long-term clinical outcome of gastric MALT lymphoma after eradication of Helicobacter pylori: a multicentre cohort follow-up study of 420 patients in Japan. Gut 2012; 61: 507-513
    CrossrefPubMedSearch in Google Scholar
  • 29 Correa P. A human model of gastric carcinogenesis. Cancer Res 1988; 48: 3554-3560
    PubMedSearch in Google Scholar
  • 30 Ekström AM, Held M, Hansson LE et al. Helicobacter pylori in gastric cancer established by CagA immunoblot as a marker of past infection. Gastroenterology 2001; 121: 784-791
    CrossrefPubMedSearch in Google Scholar
  • 31 Wong BC, Lam SK, Wong WM et al. Helicobacter pylori eradication to prevent gastric cancer in a high-risk region of China: a randomized controlled trial. JAMA 2004; 291: 187-194
    CrossrefPubMedSearch in Google Scholar
  • 32 Wroblewski LE, Peek RM, Wilson KT. Helicobacter pylori and gastric cancer: factors that modulate disease risk. Clin Microbiol Rev 2010; 23: 713-739
    CrossrefPubMedSearch in Google Scholar
  • 33 Fuccio L, Zagari RM, Minardi ME et al. Systematic review: Helicobacter pylori eradication for the prevention of gastric cancer. Aliment Pharmacol Ther 2007; 25: 133-141
    CrossrefPubMedSearch in Google Scholar
  • 34 Fukase K, Kato M, Kikuchi S et al. Effect of eradication of Helicobacter pylori on incidence of metachronous gastric carcinoma after endoscopic resection of early gastric cancer: an open-label, randomised controlled trial. Lancet 2008; 372: 392-397
    CrossrefPubMedSearch in Google Scholar
  • 35 Malfertheiner P, Fry LC, Mönkemüller K. Can gastric cancer be prevented by Helicobacter pylori eradication?. Best Pract Res Clin Gastroenterol 2006; 20: 709-719
    CrossrefPubMedSearch in Google Scholar
  • 36 de Martel C, Ferlay J, Franceschi S et al. Global burden of cancers attributable to infections in 2008: a review and synthetic analysis. Lancet Oncol 2012; 13: 607-615
    CrossrefPubMedSearch in Google Scholar
  • 37 Gisbert JP, Pajares JM. Review article: 13C-urea breath test in the diagnosis of Helicobacter pylori infection – a critical review. Aliment Pharmacol Ther 2004; 20: 1001-1017
    CrossrefPubMedSearch in Google Scholar
  • 38 Gisbert JP, Pajares JM. 13C-urea breath test in the management of Helicobacterpylori infection. Dig Liver Dis 2005; 37: 899-906
    CrossrefPubMedSearch in Google Scholar
  • 39 Calvet X, Lario S, Ramírez-Lázaro MJ et al. Accuracy of monoclonal stool tests for determining cure of Helicobacter pylori infection after treatment. Helicobacter 2010; 15: 201-205
    CrossrefPubMedSearch in Google Scholar
  • 40 Cambau E, Allerheiligen V, Coulon C et al. Evaluation of a new test, genotype HelicoDR, for molecular detection of antibiotic resistance in Helicobacter pylori. J Clin Microbiol 2009; 47: 3600-3607
    CrossrefPubMedSearch in Google Scholar
  • 41 Megraud F, Coenen S, Versporten A et al. Helicobacter pylori resistance to antibiotics in Europe and its relationship to antibiotic consumption. Gut 2013; 62: 34-42
    CrossrefPubMedSearch in Google Scholar
  • 42 Robert Koch Institut. Überblick zu aktuellen Projekten des Nationalen Referenzzentrums für Helicobacter pylori. Epidemiologisches Bulletin 2013; 3: 24-27
    PubMedSearch in Google Scholar
  • 43 Malfertheiner P, Bazzoli F, Delchier J et al. Helicobacter pylori eradication with a capsule containing bismuth subcitrate potassium, metronidazole, and tetracycline given with omeprazole versus clarithromycin-based triple therapy: a randomised, open-label, non-inferiority, phase 3 trial. Lancet 2011; 377: 905-913
    CrossrefPubMedSearch in Google Scholar